(Updated - November 9, 2015 1:57 PM EST)
Mallinckrodt (NYSE: MNK) was mentioned cautiously at Citron Research. Citron said the stock has more downside than Valeant Pharma (NYSE: VRX).
At these prices $MNK has signif more downside than $VRX-- far worse offender of the reimb sys - more to follow. VRX can't live in a vacuum— Citron Research (@CitronResearch) November 9, 2015
At these prices $MNK has signif more downside than $VRX-- far worse offender of the reimb sys - more to follow. VRX can't live in a vacuum
